Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Ocular Side Effects Linked to Ovarian Cancer Drug
A recent study presented at the American Academy of Ophthalmology (AAO) meeting in Chicago has identified significant ocular side effects associated with mirvetuximab soravtansine (Elahere), a drug approved for ovarian cancer treatment. The research, conducted by Stanford University, highlights the…
ANX007 Protects Vision in Dry AMD – AAO 2024
A new investigational drug, ANX007, offers hope for the millions of people suffering from geographic atrophy, a severe form of dry age-related macular degeneration (AMD). The drug’s potential to reduce vision loss and protect essential retinal structures was highlighted at…
Long-Term Antiviral Therapy for Ocular Shingles
A new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania and the NYU Grossman School of Medicine suggests that taking an antiviral medication for a year can help prevent vision loss caused by…
New Drug Targets for Inherited Retinal Diseases Identified
An international team of researchers has discovered new drug targets for inherited retinal diseases, such as retinitis pigmentosa (RP). Using advanced proteomics, they identified common critical pathways in different disease models, offering hope for broad-spectrum treatments. Key Findings in Retinitis…
Ophthalmic Drug Delivery Summit 2024
In January, over 60 world-renowned experts in ophthalmic drug delivery will gather in San Francisco for the 3rd annual Ophthalmic Drug Delivery Summit. This industry-focused event aims to advance effectiveness, durability, and minimally invasive techniques in retinal drug delivery. Key…
Reducing the Carbon Footprint of Intravitreal Injections
Adopting specific treatment protocols, minimizing travel for patients and staff, and reducing unnecessary use of personal protective equipment (PPE) can significantly decrease the carbon footprint of intravitreal injections. This topic was discussed in detail by Redmer van Leeuwen, MD, PhD,…
Ocular Therapeutix Progresses Phase 3 OTX-TKI Trial
Ocular Therapeutix has announced that over 300 patients have been randomized in the SOL-1 Phase 3 trial for OTX-TKI (AXPAXLI, axitinib intravitreal implant). This marks a critical milestone in the development of the first registrational trial for OTX-TKI as a…
EyePoint Begins Phase 3 LUCIA Trial for Wet AMD
EyePoint Pharmaceuticals has successfully dosed the first patient in the LUCIA trial, marking the start of the company’s second global Phase 3 clinical study for Duravyu (formerly EYP-1901), an investigational sustained-release therapy for wet age-related macular degeneration (wet AMD). Duravyu:…
Nicox Completes Denali Phase 3 Enrollment
Nicox has announced the completion of patient enrollment in China for the Denali Phase 3 trial, which evaluates the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension. The screening process in China is now…
ONS-5010 Falls Short in NORSE EIGHT Trial for Wet AMD
ONS-5010 (LYTENAVA), an ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration (AMD), failed to meet the noninferiority endpoint in the NORSE EIGHT clinical trial, according to preliminary topline results announced by Outlook Therapeutics. About the NORSE EIGHT Trial…